Biblio

Author Title Type [ Year(Asc)]
Filters: Author is García-Cadenas, Irene  [Clear All Filters]
2023
Regalado-Artamendi I, García-Fasanella M, Medina L, Fernández-Sojo J, Esquirol A, García-Cadenas I, Martino R, Briones J, Sierra J, Novelli S. Age, CD34+ cell dose, conditioning and pre-transplant cytopenias can help predict transfusion support in lymphoma patients undergoing autologous stem cell transplantation. Vox Sang. 2023.
Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, et al. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023.
Piñana JLuis, Vázquez L, Calabuig M, López-Corral L, Martin-Martin G, Villalon L, Sanz-Linares G, Conesa-Garcia V, Sanchez-Salinas A, Gago B, et al. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood Cancer J. 2023;13(1):8.
Piñana JLuis, Heras I, Aiello TFrancesco, García-Cadenas I, Vázquez L, López-Jiménez J, Chorão P, Aroca C, Garcia-Vidal C, Arroyo I, et al. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients. Viruses. 2023;15(10).
Piñana JL, Pérez A, Chorão P, Guerreiro M, García-Cadenas I, Solano C, Martino R, Navarro D. Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances. Transpl Infect Dis. 2023:e14117.
Redondo S, García-Cadenas I, Vila A, Esquirol A, Portos JM, Novelli S, Saavedra S, Moreno C, Garrido A, Arguello-Tomas M, et al. Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI. Eur J Haematol. 2023.
2022
Albiol N, Barata A, Aso O, Gómez-Pérez L, Triquell M, Roch N, Lázaro E, Esquirol A, González I, López-Contreras J, et al. mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2022.
Piñana JLuis, López-Corral L, Martino R, Vázquez L, Pérez A, Martin-Martin G, Gago B, Sanz-Linares G, Sanchez-Salinas A, Villalon L, et al. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. J Hematol Oncol. 2022;15(1):54.
2020
Hernández-Boluda J-C, Pereira A, Alvarez-Larran A, Martín A-A, Benzaquen A, Aguirre L, Mora E, González P, Mora J, Dorado N, et al. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model: Prognostication in myelofibrosis. Biol Blood Marrow Transplant. 2020.
Piñana JLuis, Martino R, García-García I, Parody R, Morales MDolores, Benzo G, Gómez-Catalan I, Coll R, De La Fuente I, Luna A, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21.
2019
Ribera J-M, García O, Moreno M-J, Barba P, García-Cadenas I, Mercadal S, Montesinos P, Barrios M, González-Campos J, Martínez-Carballeira D, et al. Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. Cancer. 2019.